EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Safety profile of paediatric COVID‐19 vaccines: An analysis of the US Vaccine Adverse Event Reporting System

Victoria Nikitina iD, Greta Santi Laurini iD, Nicola Montanaro iD, Domenico Motola iD

Acta Paediatrica · 2023

DOI: 10.1111/apa.16954 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Paediatrica, 2023. Verfasst von Victoria Nikitina und 3 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Pharmacology, Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy. Hauptthemen laut MEDLINE: Adverse Drug Reaction Reporting Systems, COVID-19 Vaccines, COVID-19. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To provide further evidence on the safety profile of COVID‐19 vaccines in paediatrics by analysing the spontaneous reports of adverse effects related to these vaccines.

Methods

Reports related to US paediatric population (from 0 to 17 years) vaccinated with authorised COVID‐19 vaccines were extracted from Vaccine Adverse Event Reporting System from December 2020 to 17 November 2022. We conducted a descriptive analysis of Adverse Events Following Immunization (AEFI), calculating reporting rate of serious AEFIs and focusing on myocarditis and Guillain‐Barré Syndrome after mRNA COVID‐19 vaccines.

Results

Overall, 52 720 reports were retrieved: 77% (40541)‐Pfizer‐BioNTech, 19% (10083)‐Moderna, a small proportion for other vaccines 4% (2096). Most of AEFIs were non‐serious and listed in corresponding SPCs. Of serious AEFIs, 96% were related to the Pfizer‐BioNTech vaccine. Roughly 91% (47874) were related to people from 6 to 17 years, a small percentage of 9% (4773) to the younger group (0–5 years). In both groups, most of the reports were related to mRNA vaccines and the percentage of AEFIs experienced by females were similar to males.

Conclusions

Data showed that events most frequently reported were non‐serious and listed in the corresponding SPCs, extending the evidence of safety of COVID‐19 vaccines authorised in the United States in children.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adverse Drug Reaction Reporting SystemsCOVID-19 VaccinesCOVID-19HumansChildAdolescentChild, PreschoolInfantUnited StatesMaleFemaleInfant, NewbornGuillain-Barre Syndrome

Stichwörter der Autor:innen

COVID-19COVID-19 vaccineschildrenpaediatricpharmacovigilance

Substanzen

COVID-19 Vaccines

Autor:innen und Institutionen

  • Unit of Pharmacology, Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy.
  • Alma Mater Studiorum University di Bologna, Bologna, Italy.

ORCID-Profile: Victoria Nikitina, Greta Santi Laurini, Nicola Montanaro, Domenico Motola

Zitieren

APA

Nikitina, V., Santi Laurini, G., Montanaro, N., & Motola, D. (2023). Safety profile of paediatric COVID‐19 vaccines: An analysis of the US Vaccine Adverse Event Reporting System. Acta Paediatrica. https://doi.org/10.1111/apa.16954

Vancouver

Nikitina V, Santi Laurini G, Montanaro N, Motola D. Safety profile of paediatric COVID‐19 vaccines: An analysis of the US Vaccine Adverse Event Reporting System. Acta Paediatrica. 2023. doi:10.1111/apa.16954

BibTeX
@article{Nikitina2023,
  author = {Nikitina, Victoria and Santi Laurini, Greta and Montanaro, Nicola and Motola, Domenico},
  title = {Safety profile of paediatric COVID‐19 vaccines: An analysis of the US Vaccine Adverse Event Reporting System},
  journal = {Acta Paediatrica},
  year = {2023},
  doi = {10.1111/apa.16954}
}
Kostenlos starten →